The Experts below are selected from a list of 12492 Experts worldwide ranked by ideXlab platform
Klaus Pantel - One of the best experts on this subject based on the ideXlab platform.
-
Liquid Biopsy and minimal residual disease latest advances and implications for cure
Nature Reviews Clinical Oncology, 2019Co-Authors: Klaus Pantel, Catherine AlixpanabieresAbstract:Liquid Biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive Liquid Biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of Liquid Biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. In this Review, we discuss the key technologies that can be used to detect and characterize CTCs in surveillance of MRD and provide a brief overview of similar roles of ctDNA analyses. We then focus on the current clinical data on the use of CTCs and ctDNA in the detection and monitoring of MRD and in obtaining information on therapeutic targets and resistance mechanisms relevant to the management of individual patients with cancer. In this Review, Pantel and Alix-Panabieres provide an overview of approaches for the detection and characterization of minimal residual disease (MRD) using circulating tumour cells and circulating tumour DNA. They also discuss the clinical implications of such Liquid Biopsy approaches to MRD monitoring for the management of patients with cancer.
-
Aktuelles zur Liquid Biopsy
2018Co-Authors: Natalie Reimers, Claudia Hille, Klaus PantelAbstract:Die Liquid Biopsy ist ein Verfahren, mit dem sich Zellen und deren Bestandteile nachweisen lassen, die von Tumoren in Korperflussigkeiten wie das Blut abgegeben werden. Mit der Flussigbiopsie ist es zum Teil auch heute schon moglich, Targets fur eine personalisierte Therapie aus dem Blut zu identifizieren oder den Verlauf einer Behandlung zu uberwachen. Langfristig konnte sich die Liquid Biopsy auch in der Krebsfruherkennung bewahren — fur diese Anwendung bestehen aktuell aber noch besonders grose Herausforderungen.
-
Liquid Biopsy current status and future perspectives
Onkologie, 2017Co-Authors: Sonja Mader, Klaus PantelAbstract:Cancer patients usually receive therapies according to their primary tumor's molecular traits. These characteristics may change during the molecular evolution of distant metastases as the leading cause of cancer deaths. Primary tumor tissue, if accessible at all, does not always provide enough information to stratify individual patients to the most promising therapy. Re-analysis of metastatic lesions by needle Biopsy is possible but invasive, and limited by the known intra-patient heterogeneity of individual lesions. These hurdles might be overcome by analyzing tumor cells or tumor cell products in blood samples (Liquid Biopsy), which in principle might reflect all subclones present at that specific time point and allow sequential monitoring of disease evolution. Liquid biopsies inform on circulating tumor cells as well as tumor-derived cell-free nucleic acids, exosomes and platelets. Here, we introduce the different approaches of blood-based Liquid biopsies and discuss the clinical applications in oncology.
-
clinical applications of circulating tumor cells and circulating tumor dna as Liquid Biopsy
Cancer Discovery, 2016Co-Authors: Catherine Alixpanabieres, Klaus PantelAbstract:“Liquid Biopsy” focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are, to date, the cornerstones of Liquid Biopsy diagnostics. The present review focuses on key areas of clinical applications of CTCs and ctDNA, including detection of cancer, prediction of prognosis in patients with curable disease, monitoring systemic therapies, and stratification of patients based on the detection of therapeutic targets or resistance mechanisms. Significance: The application of CTCs and ctDNA for the early detection of cancer is of high public interest, but it faces serious challenges regarding specificity and sensitivity of the current assays. Prediction of prognosis in patients with curable disease can already be achieved in several tumor entities, particularly in breast cancer. Monitoring the success or failure of systemic therapies (i.e., chemotherapy, hormonal therapy, or other targeted therapies) by sequential measurements of CTCs or ctDNA is also feasible. Interventional studies on treatment stratification based on the analysis of CTCs and ctDNA are needed to implement Liquid Biopsy into personalized medicine. Cancer Discov; 6(5); 479–91. ©2016 AACR.
-
tumor educated platelets as Liquid Biopsy in cancer patients
Cancer Cell, 2015Co-Authors: Simon A Joosse, Klaus PantelAbstract:Real-time monitoring of changes in cells or cell products released from malignant lesions into the blood has opened new diagnostic avenues ("Liquid Biopsy"). In this issue of Cancer Cell, Best and colleagues describe that tumor-associated blood platelets provide specific information on the location and molecular composition of the primary tumor.
Simon A Joosse - One of the best experts on this subject based on the ideXlab platform.
-
techniques of using circulating tumor dna as a Liquid Biopsy component in cancer management
Computational and structural biotechnology journal, 2018Co-Authors: Maha Elazezy, Simon A JoosseAbstract:Abstract Precision medicine in the clinical management of cancer may be achieved through the diagnostic platform called “Liquid Biopsy”. This method utilizes the detection of biomarkers in blood for prognostic and predictive purposes. One of the latest blood born markers under investigation in the field of Liquid Biopsy in cancer patients is circulating tumor DNA (ctDNA). ctDNA is released by tumor cells through different mechanisms and can therefore provide information about the genomic make-up of the tumor currently present in the patient. Through longitudinal ctDNA-based Liquid biopsies, tumor dynamics may be monitored to predict and assess drug response and/or resistance. However, because ctDNA is highly fragmented and because its concentration can be extremely low in a high background of normal circulating DNA, screening for clinical relevant mutations is challenging. Although significant progress has been made in advancing the detection and analysis of ctDNA in the last few years, the current challenges include standardization and increasing current techniques to single molecule sensitivity in combination with perfect specificity. This review focuses on the potential role of ctDNA in the clinical management of cancer patients, the current technologies that are being employed, and the hurdles that still need to be taken to achieve ctDNA-based Liquid Biopsy towards precision medicine.
-
tumor educated platelets as Liquid Biopsy in cancer patients
Cancer Cell, 2015Co-Authors: Simon A Joosse, Klaus PantelAbstract:Real-time monitoring of changes in cells or cell products released from malignant lesions into the blood has opened new diagnostic avenues ("Liquid Biopsy"). In this issue of Cancer Cell, Best and colleagues describe that tumor-associated blood platelets provide specific information on the location and molecular composition of the primary tumor.
Bakhos A Tannous - One of the best experts on this subject based on the ideXlab platform.
-
allowance of tumor educated platelets for multiclass Liquid Biopsy based diagnosis of cancer
Journal of Clinical Oncology, 2015Co-Authors: Myron G Best, Irsan E Kooi, Jonas Nilsson, Bart A Westerman, Bauke Ylstra, Josephine C Dorsman, Egbert F Smit, Henk M W Verheul, Jaap C Reijneveld, Bakhos A TannousAbstract:Allowance of tumor-educated platelets for multiclass Liquid Biopsy-based diagnosis of cancer
Catherine Alixpanabieres - One of the best experts on this subject based on the ideXlab platform.
-
the future of Liquid Biopsy
Nature, 2020Co-Authors: Catherine AlixpanabieresAbstract:The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabieres. The challenge now is to make Liquid Biopsy a standard clinical tool. The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabieres. The challenge now is to make Liquid Biopsy a standard clinical tool.
-
Liquid Biopsy and minimal residual disease latest advances and implications for cure
Nature Reviews Clinical Oncology, 2019Co-Authors: Klaus Pantel, Catherine AlixpanabieresAbstract:Liquid Biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive Liquid Biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of Liquid Biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. In this Review, we discuss the key technologies that can be used to detect and characterize CTCs in surveillance of MRD and provide a brief overview of similar roles of ctDNA analyses. We then focus on the current clinical data on the use of CTCs and ctDNA in the detection and monitoring of MRD and in obtaining information on therapeutic targets and resistance mechanisms relevant to the management of individual patients with cancer. In this Review, Pantel and Alix-Panabieres provide an overview of approaches for the detection and characterization of minimal residual disease (MRD) using circulating tumour cells and circulating tumour DNA. They also discuss the clinical implications of such Liquid Biopsy approaches to MRD monitoring for the management of patients with cancer.
-
clinical applications of circulating tumor cells and circulating tumor dna as Liquid Biopsy
Cancer Discovery, 2016Co-Authors: Catherine Alixpanabieres, Klaus PantelAbstract:“Liquid Biopsy” focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are, to date, the cornerstones of Liquid Biopsy diagnostics. The present review focuses on key areas of clinical applications of CTCs and ctDNA, including detection of cancer, prediction of prognosis in patients with curable disease, monitoring systemic therapies, and stratification of patients based on the detection of therapeutic targets or resistance mechanisms. Significance: The application of CTCs and ctDNA for the early detection of cancer is of high public interest, but it faces serious challenges regarding specificity and sensitivity of the current assays. Prediction of prognosis in patients with curable disease can already be achieved in several tumor entities, particularly in breast cancer. Monitoring the success or failure of systemic therapies (i.e., chemotherapy, hormonal therapy, or other targeted therapies) by sequential measurements of CTCs or ctDNA is also feasible. Interventional studies on treatment stratification based on the analysis of CTCs and ctDNA are needed to implement Liquid Biopsy into personalized medicine. Cancer Discov; 6(5); 479–91. ©2016 AACR.
-
real time Liquid Biopsy in cancer patients fact or fiction
Cancer Research, 2013Co-Authors: Klaus Pantel, Catherine AlixpanabieresAbstract:Distant metastases harbor unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intrapatient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practice in oncology) or, if possible, even reevaluation of tumor characteristics based on the Biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. Here, we propose that this dilemma can be solved by a new diagnostic concept: Liquid Biopsy, that is, analysis of therapeutic targets and drug resistance–conferring gene mutations on circulating tumor cells (CTC) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. We discuss the current challenges and future perspectives of CTCs and ctDNA as biomarkers in clinical oncology. Both CTCs and ctDNA are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the Liquid Biopsy concept will contribute to a better understanding and clinical management of drug resistance in patients with cancer. Cancer Res; 73(21); 6384–8. ©2013 AACR.
Tingbo Liang - One of the best experts on this subject based on the ideXlab platform.
-
Liquid Biopsy in pancreatic cancer the beginning of a new era
Oncotarget, 2018Co-Authors: Dipesh Kumar Yadav, Rajesh Kumar Yadav, Alina Singh, Guogang Li, Wei Chen, Tingbo LiangAbstract:// Dipesh Kumar Yadav 1 , Xueli Bai 1 , Rajesh Kumar Yadav 2 , Alina Singh 3 , Guogang Li 1 , Tao Ma 1 , Wei Chen 1 and Tingbo Liang 1 1 Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China 2 Department of Pharmacology, Gandaki Medical College, Tribhuwan University, Institute of Medicine, Pokhara 33700, Nepal 3 Department of Surgery, Bir Hospital, National Academy of Medical Science, Kanti Path, Kathmandu 44600, Nepal Correspondence to: Tingbo Liang, email: liangtingbo@zju.edu.cn Keywords: Liquid Biopsy; pancreatic cancer; circulating tumor cells; circulating tumor nucleic acids; exosomes Received: October 26, 2017 Accepted: February 25, 2018 Published: June 01, 2018 ABSTRACT With dismal survival rate pancreatic cancer remains one of the most aggressive and devastating malignancy. Predominantly, due to the absence of a dependable methodology for early identification and limited therapeutic options for advanced disease. However, it takes over 17 years to develop pancreatic cancer from initiation of mutation to metastatic cancer; therefore, if diagnosed early; it may increase overall survival dramatically, thus, providing a window of opportunity for early detection. Recently, genomic expression analysis defined 4 subtypes of pancreatic cancer based on mutated genes. Hence, we need simple and standard, minimally invasive test that can monitor those altered genes or their associated pathways in time for the success of precision medicine, and Liquid Biopsy seems to be one answer to all these questions. Again, Liquid Biopsy has an ability to pair with genomic tests. Additionally, Liquid Biopsy based development of circulating tumor cells derived xenografts, 3D organoids system, real-time monitoring of genetic mutations by circulating tumor DNA and exosome as the targeted drug delivery vehicle holds lots of potential for the treatment and cure of pancreatic cancer. At present, diagnosis of pancreatic cancer is frantically done on the premise of CA19-9 and radiological features only, which doesn’t give a picture of genetic mutations and epigenetic alteration involved. In this manner, the current diagnostic paradigm for pancreatic cancer diagnosis experiences low diagnostic accuracy. This review article discusses the current state of Liquid Biopsy in pancreatic cancer as diagnostic and therapeutic tools and future perspectives of research in the light of circulating tumor cells, circulating tumor DNA and exosomes.